The role of cholesterol efflux in mechanisms of endothelial protection by HDL

Current Opinion in Lipidology

Volumn 23, Issue 3, 2012, Pages 182-189

  Prosser, Hamish C ^a,c   Ng, Martin K C ^a,b,c   Bursill, Christina A ^a,c  

^a HEART RESEARCH INSTITUTE   (Australia)

^b ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^c UNIVERSITY OF SYDNEY   (Australia)

Author keywords

cholesterol efflux; endothelial nitric oxide synthase; endothelium; HDL; signaling

Indexed keywords

ABC TRANSPORTER A1; ABC TRANSPORTER G1; APOLIPOPROTEIN A1; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN; OXYSTEROL; SCAVENGER RECEPTOR BI;

ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTERY ENDOTHELIUM; ATHEROSCLEROTIC PLAQUE; CHOLESTEROL TRANSPORT; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN LIPID INTERACTION; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; ATP-BINDING CASSETTE TRANSPORTERS; CHOLESTEROL; ENDOTHELIUM; HUMANS; LIPOPROTEINS, HDL; SCAVENGER RECEPTORS, CLASS B; SIGNAL TRANSDUCTION;

EID: 84861096803     PISSN: 09579672     EISSN: 14736535     Source Type: Journal    
DOI: 10.1097/MOL.0b013e328352c4dd     Document Type: Review

References (79)

1. Gordon DJ, Rifkind BM. High-density lipoprotein: the clinical implications of recent studies. N Engl J Med 1989; 321:1311-1316. (Pubitemid 19267219)
2. Tardif JC, Grégoire J, L'Allier PL, et al. Effects of reconstituted high-density lipoprotein infusions on coronary atherosclerosis: a randomized controlled trial. JAMA 2007; 297:1675-1682. (Pubitemid 46631626)
3. Berge KG, Canner PL, Hainline AJ. High-density lipoprotein cholesterol and prognosis after myocardial infarction. Circulation 1978; 66:1176-1178.
4. Gordon T, Castelli WP, Hjortland MC, et al. High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am J Med 1977; 62:707-714. (Pubitemid 8110784)
5. Natarajan P, Ray KK, Cannon CP. High-density lipoprotein and coronary heart disease: current and future therapies. J Am Coll Cardiol 2010; 55:1283-1299.
6. Assmann G, Gotto AM Jr. HDL cholesterol and protective factors in atherosclerosis. Circulation 2004; 109:III8-III14. (Pubitemid 38786437)
7. Barter PJ, Nicholls SJ, Rye KA, et al. Antiinflammatory properties of HDL. Circ Res 2004; 95:764-772. (Pubitemid 39390578)
8. Kimura T, Tomura H, Sato K, et al. Mechanism and role of high density lipoprotein-induced activation of AMP-activated protein kinase in endothelial cells. J Biol Chem 2010; 285:4387-4397.
9. Li D, Weng S, Yang B, et al. Inhibition of arterial thrombus formation by ApoA1 Milano. Arterioscler Thromb Vasc Biol 1999; 19:378-383. (Pubitemid 29072754)
10. Naqvi TZ, Shah PK, Ivey PA, et al. Evidence that high-density lipoprotein cholesterol is an independent predictor of acute platelet-dependent thrombus formation. Am J Cardiol 1999; 84:1011-1017. (Pubitemid 29505367)
11. Navab M, Hama SY, Cooke CJ, et al. Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein: step 1. J Lipid Res 2000; 41:1481-1494.
12. Nofer JR, Levkau B, Wolinska I, et al. Suppression of endothelial cell apoptosis by high density lipoproteins (HDL) and HDL-associated lysosphin-golipids. J Biol Chem 2001; 276:34480-34485.
13. Seetharam D, Mineo C, Gormley AK, et al. High-density lipoprotein promotes endothelial cell migration and reendothelialization via scavenger receptor-B type I. Circ Res 2006; 98:63-72. (Pubitemid 43970204)
14. Nofer JR, Van Der Giet M, Tölle M, et al. HDL induces NO-dependent vasorelaxation via the lysophospholipid receptor S1P3. J Clin Invest 2004; 113:569-581. (Pubitemid 38542506)
15. Sumi M, Sata M, Miura SI, et al. Reconstituted high-density lipoprotein stimulates differentiation of endothelial progenitor cells and enhances ischemia-induced angiogenesis. Arterioscler Thromb Vasc Biol 2007; 27:813-818. (Pubitemid 46606711)
16. Yuhanna IS, Zhu Y, Cox BE, et al. High-density lipoprotein binding to scavenger receptor-BI activates endothelial nitric oxide synthase. Nat Med 2001; 7:853-857. (Pubitemid 32691642)
17. Mineo C, Shaul PW. HDL stimulation of endothelial nitric oxide synthase: a novel mechanism of HDL action. Trends Cardiovasc Med 2003; 13:226-231. (Pubitemid 36960169)
18. Choi HY, Rahmani M, Wong BW, et al. ATP-binding cassette transporter A1 expression and apolipoprotein A-I binding are impaired in intima-type arterial smooth muscle cells. Circulation 2009; 119:3223-3231.
19. Fielding PE, Nagao K, Hakamata H, et al. A two-step mechanism for free cholesterol and phospholipid efflux from human vascular cells to apolipopro-tein A-1. Biochemistry 2000; 39:14113-14120.
20. Navab M, Reddy ST, Van Lenten BJ, Fogelman AM. HDL and cardiovascular disease: atherogenic and atheroprotective mechanisms. Nat Rev Cardiol 2011; 8:222-232.
21. Tall AR. Cholesterol efflux pathways and other potential mechanisms involved in the athero-protective effect of high density lipoproteins. J Intern Med 2008; 263:256-273. (Pubitemid 351207349)
22. Savion N, Kotev-Emeth S. Cholesterol efflux from and high-density- lipopro-teins binding to cultured bovine vascular endothelial cells are higher than with vascular smooth muscle cells. Eur J Biochem 1989; 183:363-370. (Pubitemid 19199670)
23. Vantourout P, Radojkovic C, Lichtenstein L, et al. Ecto-F1-ATPase: a moonlighting protein complex and an unexpected apoA-I receptor. World J Gastro-enterol 2010; 16:5925-5935.
24. Wang N,Lan D, Chen W, et al. ATP-binding cassette transportersG1 and G4 mediate cellular cholesterol efflux to high-density lipoproteins. Proc Natl Acad Sci USA 2004; 101:9774-9779. (Pubitemid 38869312)
25. Schultz JR, Verstuyft JG, Gong EL, et al. Protein composition determines the antiatherogenic properties of HDL in transgenic mice. Nature 1993; 365: 762-764. (Pubitemid 23339884)
26. Gelissen IC, Harris M, Rye K-A, et al. ABCA1 and ABCG1 synergize to mediate cholesterol export to apoA-I. Arterioscler Thromb Vasc Biol 2006; 26:534-540.
27. Lin Y-C, Ma C, Hsu W-C, et al. Molecular interaction between caveolin-1 and ABCA1 on high-density lipoprotein-mediated cholesterol efflux in aortic endothelial cells. Cardiovasc Res 2007; 75:575-583. (Pubitemid 47080965)
28. Lin Y-C, Lin C-H, Kuo C-Y, Yang VC. ABCA1 modulates the oligomeriza-tion and Golgi exit of caveolin-1 during HDL-mediated cholesterol efflux in aortic endothelial cells. Biochem Biophys Res Commun 2009; 382:189-195.
29. Feron O, Dessy C, Moniotte S, et al. Hypercholesterolemia decreases nitric oxide production by promoting the interaction of caveolin and endothelial nitric oxide synthase. J Clin Invest 1999; 103:897-905. (Pubitemid 29152636)
30. Gonzalez E, Nagiel A, Lin AJ, et al. Small interfering RNA-mediated down-regulation of caveolin-1 differentially modulates signaling pathways in en-dothelial cells. J Biol Chem 2004; 279:40659-40669. (Pubitemid 39287660)
31. Joyce CW, Amar MJ, Lambert G, et al. The ATP binding cassette transporter A1 (ABCA1) modulates the development of aortic atherosclerosis in C57BL/6 and apoE-knockout mice. Proc Natl Acad Sci USA 2002; 99:407-412. (Pubitemid 34060374)
32. Vaisman BL, Demosky SJ, Stonik JA, et al. Endothelial expression of human ABCA1 in mice increases plasma HDL cholesterol and reduces diet-induced atherosclerosis. J Lipid Res 2012; 53:158-167.
33. Liao H, Langmann T, Schmitz G, Zhu Y. Native LDL upregulation of ATP-binding cassette transporter-1 in human vascular endothelial cells. Arterios-cler Thromb Vasc Biol 2002; 22:127-132. (Pubitemid 34076243)
34. Tabet F, Remaley AT, Segaliny AI, et al. The 5A apolipoprotein A-I mimetic peptide displays antiinflammatory and antioxidant properties in vivo and in vitro. Arterioscler Thromb Vasc Biol 2010; 30:246-252.
35. Sethi AA, Stonik JA, Thomas F, et al. Asymmetry in the lipid affinity of bihelical amphipathic peptides. A structural determinant for the specificity of ABCA1-dependent cholesterol efflux by peptides. J Biol Chem 2008; 283:32273-32282.
36. Haidar B, Denis M, Marcil M, et al. Apolipoprotein A-I activates cellular cAMP signaling through the ABCA1 transporter. J Biol Chem 2004; 279:9963-9969. (Pubitemid 38372598)
37. See RH, Caday-Malcolm RA, Singaraja RR, et al. Protein kinase A site-specific phosphorylation regulates ATP-binding cassette A1 (ABCA1)-mediated phospholipid efflux. J Biol Chem 2002; 277:41835-41842. (Pubitemid 35257494)
38. Tang C, Vaughan AM, Oram JF. Janus kinase 2 modulates the apolipoprotein interactions with ABCA1 required for removing cellular cholesterol. J Biol Chem 2004; 279:7622-7628. (Pubitemid 38294642)
39. Wang Y, Oram JF. Unsaturated fatty acids phosphorylate and destabilize ABCA1 through a protein kinase Cd pathway. J Lipid Res 2007; 48:1062-1068. (Pubitemid 46708673)
40. Yamauchi Y, Hayashi M, Abe-Dohmae S, Yokoyama S. Apolipoprotein A-I activates protein kinase Ca signaling to phosphorylate and stabilize ATP binding cassette transporter A1 for the high density lipoprotein assembly. J Biol Chem 2003; 278:47890-47897. (Pubitemid 37523237)
41. Nofer J-R, Feuerborn R, Levkau B, et al. Involvement of Cdc42 signaling in ApoA-I-induced cholesterol efflux. J Biol Chem 2003; 278:53055-53062. (Pubitemid 38035908)
42. Oram JF, Heinecke JW. ATP-binding cassette transporter A1: a cell cholesterol exporter that protects against cardiovascular disease. Physiol Rev 2005; 85:1343-1372. (Pubitemid 41362273)
43. Liu D, Ji L, Tong X, et al. Human apolipoprotein A-I induces cyclooxygenase-2 expression and prostaglandin I-2 release in endothelial cells through ATP-binding cassette transporter A1. Am J Physiol Cell Physiol 2011; 301:C739-C748.
44. Norata GD, Callegari E, Inoue H, Catapano AL. HDL3 induces cyclooxygen-ase-2 expression and prostacyclin release in human endothelial cells via a p38 MAPK/CRE-dependent pathway: effects on COX-2/PGI-synthase coupling. Arterioscler Thromb Vasc Biol 2004; 24:871-877. (Pubitemid 38620865)
45. Smith LH, Boutaud O, Breyer B, et al. Cyclooxygenase-2-dependent pros-tacyclin formation is regulated by low density lipoprotein cholesterol in vitro. Arterioscler Thromb Vasc Biol 2002; 22:983-988. (Pubitemid 34655227)
46. Hansson GK, Björkholm M. Tackling two diseases with HDL. Science 2010; 328:1641-1642.
47. Terasaka N, Yu S, Yvan-Charvet L, et al. ABCG1 and HDL protect against endothelial dysfunction in mice fed a high-cholesterol diet. J Clin Invest 2008; 118:3701-3713.
48. Westerterp M, Koetsveld J, Yu S, et al. Increased atherosclerosis in mice with vascular ATP-binding cassette transporter G1 deficiency: brief report. Arterioscler Thromb Vasc Biol 2010; 30:2103-2105.
49. Whetzel AM, Sturek JM, Nagelin MH, et al. ABCG1 deficiency in mice promotes endothelial activation and monocyte-endothelial interactions. Arterioscler Thromb Vasc Biol 2010; 30:809-817.
50. Terasaka N, Westerterp M, Koetsveld J, et al. ATP-binding cassette transporter G1 and high-density lipoprotein promote endothelial NO synthesis through a decrease in the interaction of caveolin-1 and endothelial NO synthase. Arterioscler Thromb Vasc Biol 2010; 30:2219-2225.
51. Acton S, Rigotti A, Landschulz KT, et al. Identification of scavenger receptor SR-BI as a high density lipoprotein receptor. Science 1996; 271:518-520.
52. Braun A, Trigatti BL, Post MJ, et al. Loss of SR-BI expression leads to the early onset of occlusive atherosclerotic coronary artery disease, spontaneous myocardial infarctions, severe cardiac dysfunction, and premature death in apolipoprotein E-deficient mice. Circ Res 2002; 90:270-276. (Pubitemid 34633927)
53. Trigatti B, Rayburn H, Viñ als M, et al. Influence of the high density lipoprotein receptor SR-BI on reproductive and cardiovascular pathophysiology. Proc Natl Acad Sci USA 1999; 96:9322-9327. (Pubitemid 29374753)
54. Huszar D, Varban ML, Rinninger F, et al. Increased LDL cholesterol and atherosclerosis in LDL receptor-deficient mice with attenuated expression of scavenger receptor B1. Arterioscler Thromb Vasc Biol 2000; 20:1068-1073. (Pubitemid 30207584)
55. Huby T, Doucet C, Dachet C, et al. Knockdown expression and hepatic deficiency reveal an atheroprotective role for SR-BI in liver and peripheral tissues. J Clin Invest 2006; 116:2767-2776. (Pubitemid 44511640)
56. Gu X, Kozarsky K, Krieger M. Scavenger receptor class B, type I-mediated [3H]cholesterol efflux to high and low density lipoproteins is dependent on lipoprotein binding to the receptor. J Biol Chem 2000; 275:29993-30001.
57. Assanasen C, Mineo C, Seetharam D, et al. Cholesterol binding, efflux, and a PDZ-interacting domain of scavenger receptor-BI mediate HDL-initiated signaling. J Clin Invest 2005; 115:969-977. (Pubitemid 40489401)
58. Uittenbogaard A, Shaul PW, Yuhanna IS, et al. High density lipoprotein prevents oxidized low density lipoprotein-induced inhibition of endothelial nitric-oxide synthase localization and activation in caveolae. J Biol Chem 2000; 275:11278-11283. (Pubitemid 30212775)
59. Shaul PW. Endothelial nitric oxide synthase, caveolae and the development of atherosclerosis. J Physiol 2003; 547:21-33. (Pubitemid 36285158)
60. Zhu W, Saddar S, Seetharam D, et al. The scavenger receptor class B type I adaptor protein PDZK1 maintains endothelial monolayer integrity. Circ Res 2008; 102:480-487. (Pubitemid 351651102)
61. Kimura T, Tomura H, Mogi C, et al. Role of scavenger receptor class B type I and sphingosine 1-phosphate receptors in high density lipoprotein-induced inhibition of adhesion molecule expression in endothelial cells. J Biol Chem 2006; 281:37457-37467. (Pubitemid 46042049)
62. Cockerill GW, Rye KA, Gamble JR, et al. High-density lipoproteins inhibit cytokine-induced expression of endothelial cell adhesion molecules. Arter-ioscler Thromb Vasc Biol 1995; 15:1987-1994.
63. Schmidt A, Geigenmuller S, Volker W, Buddecke E. The antiatherogenic and antiinflammatory effect of HDL-associated lysosphingolipids operates via Akt !NF-kappaB signaling pathways in human vascular endothelial cells. Basic Res Cardiol 2006; 101:109-116. (Pubitemid 43250802)
64. McGrath KCY, Li XH, Puranik R, et al. Role of 3beta-hydroxysteroid-delta 24 reductase in mediating antiinflammatory effects of high-density lipopro-teins in endothelial cells. Arterioscler Thromb Vasc Biol 2009; 29:877-882.
65. Mineo C, Deguchi H, Griffin JH, Shaul PW. Endothelial and antithrombotic actions of HDL. Circ Res 2006; 98:1352-1364. (Pubitemid 43948059)
66. Mineo C, Shaul PW. Role of high-density lipoprotein and scavenger receptor B type I in the promotion of endothelial repair. Trends Cardiovasc Med 2007; 17:156-161. (Pubitemid 46898843)
67. Feng Y, van Eck M, Van Craeyveld E, et al. Critical role of scavenger receptor-BI-expressing bone marrow-derived endothelial progenitor cells in the attenuation of allograft vasculopathy after human apo A-I transfer. Blood 2009; 113:755-764.
68. Noor R, Shuaib U, Wang CX, et al. High-density lipoprotein cholesterol regulates endothelial progenitor cells by increasing eNOS and preventing apoptosis. Atherosclerosis 2007; 192:92-99. (Pubitemid 46628807)
69. Petoumenos V, Nickenig G, Werner N. High-density lipoprotein exerts vas-culoprotection via endothelial progenitor cells. J Cell Mol Med 2009; 13:4623-4635.
70. Rohrer L, Ohnsorg PM, Lehner M, et al. High-density lipoprotein transport through aortic endothelial cells involves scavenger receptor BI and ATP-binding cassette transporter G1. Circ Res 2009; 104:1142-1150.
71. Ohnsorg PM, Rohrer L, Perisa D, et al. Carboxyl terminus of apolipoprotein A-I (ApoA-I) is necessary for the transport of lipid-free ApoA-I but not prelipidated ApoA-I particles through aortic endothelial cells. J Biol Chem 2011; 286:7744-7754.
72. Cavelier C, Rohrer L, von Eckardstein A. ATP-binding cassette transporter A1 modulates apolipoprotein A-I transcytosis through aortic endothelial cells. Circ Res 2006; 99:1060-1066. (Pubitemid 44729929)
73. Ohnsorg PM, Rohrer L, Perisa D, et al. Carboxyl terminus of apolipoprotein A-I (ApoA-I) is necessary for the transport of lipid-free ApoA-I but not prelipidated ApoA-I particles through aortic endothelial cells. J Biol Chem 2011; 286:7744-7754.
74. Cavelier C, Ohnsorg PM, Rohrer L, von Eckardstein A. The B-chain of cell surface F0F1 ATPase modulates ApoA-I and HDL transcytosis through aortic endothelial cells. Arterioscler Thromb Vasc Biol 2012; 32:131-139.
75. Radojkovic C, Genoux A, Pons V, et al. Stimulation of cell surface F1-ATPase activity by apolipoprotein A-I inhibits endothelial cell apoptosis and promotes proliferation. Arterioscler Thromb Vasc Biol 2009; 29:1125-1130.
76. Gordon SM, Deng J, Lu LJ, Davidson WS. Proteomic characterization of human plasma high density lipoprotein fractionated by gel filtration chroma-tography. J Proteome Res 2010; 9:5239-5249.
77. Sato K, Okajima F. Role of sphingosine 1-phosphate in antiatherogenic actions of high-density lipoprotein. World J Biol Chem 2010; 1:327-337.
78. Florentin M, Liberopoulos EN, Wierzbicki AS, Mikhailidis DP. Multiple actions of high-density lipoprotein. Curr Opin Cardiol 2008; 23:370-378. (Pubitemid 351787103)
79. Besler C, Heinrich K, Rohrer L, et al. Mechanisms underlying adverse effects of HDL on eNOS-activating pathways in patients with coronary artery disease. J Clin Invest 2011; 121:2693-2708.